109 related articles for article (PubMed ID: 20088807)
21. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
22. Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies.
Höllerhage M; Matusch A; Champy P; Lombès A; Ruberg M; Oertel WH; Höglinger GU
Exp Neurol; 2009 Nov; 220(1):133-42. PubMed ID: 19682988
[TBL] [Abstract][Full Text] [Related]
23. IFN-γ promotes τ phosphorylation without affecting mature tangles.
Li A; Ceballos-Diaz C; DiNunno N; Levites Y; Cruz PE; Lewis J; Golde TE; Chakrabarty P
FASEB J; 2015 Oct; 29(10):4384-98. PubMed ID: 26156074
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins.
Taniguchi S; Suzuki N; Masuda M; Hisanaga S; Iwatsubo T; Goedert M; Hasegawa M
J Biol Chem; 2005 Mar; 280(9):7614-23. PubMed ID: 15611092
[TBL] [Abstract][Full Text] [Related]
25. Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer's Disease and Related Tauopathies.
Kovalevich J; Cornec AS; Yao Y; James M; Crowe A; Lee VM; Trojanowski JQ; Smith AB; Ballatore C; Brunden KR
J Pharmacol Exp Ther; 2016 May; 357(2):432-50. PubMed ID: 26980057
[TBL] [Abstract][Full Text] [Related]
26. Turning down tau phosphorylation.
Fischer PM
Nat Chem Biol; 2008 Aug; 4(8):448-9. PubMed ID: 18641620
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of tau self-aggregation and neurotoxicity.
Farías G; Cornejo A; Jiménez J; Guzmán L; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):608-14. PubMed ID: 21605046
[TBL] [Abstract][Full Text] [Related]
28. [Neuropathology of tauopathy].
Yoshida M
Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
[TBL] [Abstract][Full Text] [Related]
29. Reevaluating tau reduction as a therapeutic approach for tauopathies: Insights and perspectives.
Sun X; Ogbolu VC; Baas PW; Qiang L
Cytoskeleton (Hoboken); 2024 Jan; 81(1):57-62. PubMed ID: 37819557
[TBL] [Abstract][Full Text] [Related]
30. Characterization of tau fibrillization in vitro.
Xu S; Brunden KR; Trojanowski JQ; Lee VM
Alzheimers Dement; 2010 Mar; 6(2):110-7. PubMed ID: 20298971
[TBL] [Abstract][Full Text] [Related]
31. Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies.
Combs B; Hamel C; Kanaan NM
Neurobiol Dis; 2016 Oct; 94():18-31. PubMed ID: 27260838
[TBL] [Abstract][Full Text] [Related]
32. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
[TBL] [Abstract][Full Text] [Related]
33. Increased acetylation of microtubules rescues human tau-induced microtubule defects and neuromuscular junction abnormalities in
Mao CX; Wen X; Jin S; Zhang YQ
Dis Model Mech; 2017 Oct; 10(10):1245-1252. PubMed ID: 28819043
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies.
Iqbal K; Grundke-Iqbal I
Curr Drug Targets; 2004 Aug; 5(6):495-502. PubMed ID: 15270196
[TBL] [Abstract][Full Text] [Related]
35. A mouse model to study tau pathology related with tau phosphorylation and assembly.
Engel T; Lucas JJ; Hernández F; Avila J
J Neurol Sci; 2007 Jun; 257(1-2):250-4. PubMed ID: 17362999
[TBL] [Abstract][Full Text] [Related]
36. Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.
Lin WL; Lewis J; Yen SH; Hutton M; Dickson DW
J Neurocytol; 2003 Nov; 32(9):1091-105. PubMed ID: 15044841
[TBL] [Abstract][Full Text] [Related]
37. Azure C Targets and Modulates Toxic Tau Oligomers.
Lo Cascio F; Kayed R
ACS Chem Neurosci; 2018 Jun; 9(6):1317-1326. PubMed ID: 29378132
[TBL] [Abstract][Full Text] [Related]
38. Homocysteine induces tau hyperphosphorylation in rats.
Luo Y; Zhou X; Yang X; Wang J
Neuroreport; 2007 Dec; 18(18):2005-8. PubMed ID: 18007203
[TBL] [Abstract][Full Text] [Related]
39. Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy.
Wang X; Smith K; Pearson M; Hughes A; Cosden ML; Marcus J; Hess JF; Savage MJ; Rosahl T; Smith SM; Schachter JB; Uslaner JM
PLoS One; 2018; 13(4):e0195486. PubMed ID: 29624602
[TBL] [Abstract][Full Text] [Related]
40. Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection.
Rametti A; Esclaire F; Yardin C; Cogné N; Terro F
Neurosci Lett; 2008 Mar; 434(1):93-8. PubMed ID: 18289787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
